TY - JOUR AU - Lee, D. W. PY - 2012 DA - 2012// TI - The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-1920 DO - 10.1158/1078-0432.CCR-11-1920 ID - Lee2012 ER - TY - JOUR AU - Kochenderfer, J. N. PY - 2009 DA - 2009// TI - Construction and pre-clinical evaluation of an anti-CD19 chimeric antigen receptor JO - J Immunother VL - 32 UR - https://doi.org/10.1097/CJI.0b013e3181ac6138 DO - 10.1097/CJI.0b013e3181ac6138 ID - Kochenderfer2009 ER - TY - JOUR AU - Jensen, M. PY - 1998 DA - 1998// TI - CD20 is a molecular target for scFvFc: zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy JO - Biol Blood Marrow Transplant VL - 4 UR - https://doi.org/10.1053/bbmt.1998.v4.pm9763110 DO - 10.1053/bbmt.1998.v4.pm9763110 ID - Jensen1998 ER - TY - JOUR AU - Lee, D. W. PY - 2015 DA - 2015// TI - T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)61403-3 DO - 10.1016/S0140-6736(14)61403-3 ID - Lee2015 ER - TY - JOUR AU - Grupp, S. A. PY - 2013 DA - 2013// TI - Chimeric antigen receptor–modified T cells for acute lymphoid leukemia JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1215134 DO - 10.1056/NEJMoa1215134 ID - Grupp2013 ER - TY - JOUR AU - Porter, D. L. PY - 2011 DA - 2011// TI - Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103849 DO - 10.1056/NEJMoa1103849 ID - Porter2011 ER - TY - JOUR AU - Kochenderfer, J. N. PY - 2012 DA - 2012// TI - B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-10-384388 DO - 10.1182/blood-2011-10-384388 ID - Kochenderfer2012 ER - TY - JOUR AU - Sotillo, E. PY - 2015 DA - 2015// TI - Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-1020 DO - 10.1158/2159-8290.CD-15-1020 ID - Sotillo2015 ER - TY - JOUR AU - Ginaldi, L. PY - 1998 DA - 1998// TI - Levels of expression of CD19 and CD20 in chronic B cell leukaemias JO - J Clin Pathol VL - 51 UR - https://doi.org/10.1136/jcp.51.5.364 DO - 10.1136/jcp.51.5.364 ID - Ginaldi1998 ER - TY - JOUR AU - Barrett, D. M. PY - 2011 DA - 2011// TI - Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-04-346528 DO - 10.1182/blood-2011-04-346528 ID - Barrett2011 ER - TY - JOUR AU - Wu, A. M. PY - 2001 DA - 2001// TI - Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange JO - Protein Eng VL - 14 UR - https://doi.org/10.1093/protein/14.12.1025 DO - 10.1093/protein/14.12.1025 ID - Wu2001 ER - TY - JOUR AU - Whitlow, M. PY - 1993 DA - 1993// TI - An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability JO - Protein Eng VL - 6 UR - https://doi.org/10.1093/protein/6.8.989 DO - 10.1093/protein/6.8.989 ID - Whitlow1993 ER - TY - JOUR AU - Haso, W. PY - 2013 DA - 2013// TI - Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-06-438002 DO - 10.1182/blood-2012-06-438002 ID - Haso2013 ER - TY - JOUR AU - Kuroda, H. PY - 2009 DA - 2009// TI - Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection JO - J Virol Methods VL - 157 UR - https://doi.org/10.1016/j.jviromet.2008.11.021 DO - 10.1016/j.jviromet.2008.11.021 ID - Kuroda2009 ER - TY - JOUR AU - Vilpo, J. PY - 2002 DA - 2002// TI - Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells JO - Leukemia VL - 16 UR - https://doi.org/10.1038/sj.leu.2402583 DO - 10.1038/sj.leu.2402583 ID - Vilpo2002 ER - TY - JOUR AU - Grada, Z. PY - 2013 DA - 2013// TI - TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy JO - Mol Ther Nucleic Acids VL - 2 UR - https://doi.org/10.1038/mtna.2013.32 DO - 10.1038/mtna.2013.32 ID - Grada2013 ER - TY - STD TI - Zah E, et al. T cells expressing CD19/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498–508. ID - ref17 ER - TY - JOUR AU - Hudecek, M. PY - 2013 DA - 2013// TI - Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0330 DO - 10.1158/1078-0432.CCR-13-0330 ID - Hudecek2013 ER - TY - JOUR AU - Grupp, S. A. PY - 2015 DA - 2015// TI - Durable remissions in children with relapsed/refractory aLL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019) JO - Blood VL - 126 ID - Grupp2015 ER - TY - JOUR AU - Ruella, M. PY - 2016 DA - 2016// TI - Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI87366 DO - 10.1172/JCI87366 ID - Ruella2016 ER - TY - JOUR AU - Onea, A. S. AU - Jazirehi, A. R. PY - 2016 DA - 2016// TI - CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphomas JO - Am J Cancer Res VL - 6 ID - Onea2016 ER - TY - JOUR AU - Anurathapan, U. AU - Chan, R. C. AU - Hindi, H. F. AU - Mucharla, R. AU - Bajgain, P. AU - Hayes, B. C. AU - Fisher, W. E. AU - Heslop, H. E. AU - Rooney, C. M. AU - Brenner, M. K. AU - Leen, A. M. AU - Vera, J. F. PY - 2014 DA - 2014// TI - Kinetics of tumor destruction by chimeric antigen receptor-modified T cells JO - Mol Ther VL - 22 UR - https://doi.org/10.1038/mt.2013.262 DO - 10.1038/mt.2013.262 ID - Anurathapan2014 ER - TY - JOUR AU - Jacoby, E. PY - 2016 DA - 2016// TI - CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12320 DO - 10.1038/ncomms12320 ID - Jacoby2016 ER - TY - JOUR AU - Gardner, R. PY - 2016 DA - 2016// TI - Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2015-08-665547 DO - 10.1182/blood-2015-08-665547 ID - Gardner2016 ER - TY - JOUR AU - Otero, D. C. AU - Rickert, R. C. PY - 2003 DA - 2003// TI - CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition JO - J Immunol VL - 171 UR - https://doi.org/10.4049/jimmunol.171.11.5921 DO - 10.4049/jimmunol.171.11.5921 ID - Otero2003 ER - TY - JOUR AU - Otero, D. C. AU - Anzelon, A. N. AU - Rickert, R. C. PY - 2003 DA - 2003// TI - CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals JO - J Immunol VL - 170 UR - https://doi.org/10.4049/jimmunol.170.1.73 DO - 10.4049/jimmunol.170.1.73 ID - Otero2003 ER - TY - JOUR AU - Beers, S. A. PY - 2010 DA - 2010// TI - Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2010-01-263533 DO - 10.1182/blood-2010-01-263533 ID - Beers2010 ER - TY - JOUR AU - Depoil, D. PY - 2008 DA - 2008// TI - CD19 is essential for B cell activation by promoting B cell receptor–antigen microcluster formation in response to membrane-bound ligand JO - Nat Immunol VL - 9 UR - https://doi.org/10.1038/ni1547 DO - 10.1038/ni1547 ID - Depoil2008 ER - TY - JOUR AU - Chung, E. Y. PY - 2012 DA - 2012// TI - CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis JO - J Clin Invest VL - 122 UR - https://doi.org/10.1172/JCI45851 DO - 10.1172/JCI45851 ID - Chung2012 ER - TY - JOUR AU - Poe, J. C. PY - 2012 DA - 2012// TI - A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice JO - J Immunol VL - 189 UR - https://doi.org/10.4049/jimmunol.1201000 DO - 10.4049/jimmunol.1201000 ID - Poe2012 ER -